2024 An evaluation of novel oncology approvals with a PMR/C for assessing data in racial and ethnic populations underrepresented in premarket clinical trials Read more
2024 Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and Stages Read more
2024 Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products Read more
2024 Improving Equity in Oncology Clinical Trials: Challenges and Strategies for Setting Diversity Enrollment Goals View PDF
2023 An Analysis of Dosing-Related Postmarketing Requirements for Novel Oncology Drugs Approved by the U.S. Food and Drug Administration, 2012–2022 Read more
2023 Interpreting Data from Dose-Finding Studies in Early Phase Oncology Trials to Determine the Optimal Dose View PDF
2023 Incorporating Pragmatic Elements in Study Designs to Enhance Oncology Randomized Clinical Trials View PDF